Ann-Lii Cheng

23PUBLICATIONS
99CO-AUTHORS
Predictive and prognostic markersMolecular targetsHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Cardiovascular medicine and haematology not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Mar 02, 2026
Pembrolizumab Monotherapy in Sorafenib-Treated and Treatment-Naïve Advanced Hepatocellular Carcinoma: Long-Term Follow-up of the Open-Label, Phase II KEYNOTE-224 Study.

Richard S Finn, Masatoshi Kudo, Ivan Borbath

|Dec 10, 2025
Expression of Poliovirus Receptor, the Ligand of TIGIT, Associated With Immune-Cold Tumor Microenvironment in Hepatocellular Carcinoma.

Li-Chun Lu, Yi-Hsuan Lee, Yu-Yun Shao

|Mar 25, 2025
Prompt initiation of durvalumab and tremelimumab for unresectable hepatocellular carcinoma in patients with chronic active hepatitis B: a phase 2 clinical trial.

Yu-Yun Shao, Ching-Tso Chen, Chien-Huai Chuang

|Feb 20, 2025
Corticosteroid premedication on anti-tumor effect of immune checkpoint blockade in murine hepatocellular carcinoma models.

Ying-Chun Shen, Nai-Wen Chang, Ching-Ping Yeh

|Aug 28, 2024
Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab.

Ying-Chun Shen, Tsung-Hao Liu, Alan Nicholas

|May 28, 2024
Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma.

Bruno Sangro, Peter R Galle, Robin Kate Kelley

Pageof 4

Frequent Collaborators

4 joint publications

Robin Kate Kelley

4 joint publications

Masatoshi Kudo

3 joint publications

Richard S Finn

3 joint publications

Arndt Vogel